Clinical Trials
22 trialsNCT00600015 2022-03-10
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00954278 2019-11-15
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT00647426 2019-10-22
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00547443 2019-01-10
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00543335 2018-11-15
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT00454194 2017-03-21
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed
NCT00417248 2016-07-25
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00933777 2016-05-25
SORAVE
University of Cologne
Phase 1 Completed
NCT00609804 2016-04-08
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00411671 2016-02-11
BATTLE Program: Sorafenib in Patients With NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00533585 2016-02-10
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01507740 2015-04-29
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Medical University Innsbruck
Terminated
NCT00870532 2013-11-04
Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer
National Cancer Centre, Singapore
Phase 1 Completed
NCT00922584 2013-08-21
Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Chinese Society of Lung Cancer
Phase 2 Completed
NCT00635791 2013-06-20
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
University of Colorado, Denver
Phase 1 Completed
NCT00473486 2010-01-27
PECASO
University Hospital Muenster
Phase 1/2 Terminated
NCT00532025 2009-07-28
SIRN
Johannes Gutenberg University Mainz
Phase 2 Terminated
NCT00722969 2009-03-03
Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Universitair Ziekenhuis Brussel
Phase 2 Unknown